Breakthrough Clinical Trial: Trodelvy Achieves First Major Advance in 20 Years for Early-Stage Breast Cancer Treatment

#Trodelvy Demonstrates Promise in First-line Metastatic Triple-Negative Breast Cancer Amid Gileads Variable Share Per...

In a significant advancement for cancer treatment, Gilead Sciences Inc. (NasdaqGS: GILD) has announced highly statistically significant and clinically meaningful improvements in progression-free survival (PFS) for patients with first-line metastatic triple-negative breast cancer (mTNBC) who are ineligible for checkpoint inhibitors. These findings were showcased in the recent ASCENT-03 trial, highlighting Trodelvy's potential as a groundbreaking …

Gilead's Trodelvy Achieves Solo Success in Metastatic Triple-Negative Breast Cancer Trial

In the recent Ascent-03 trial, Gilead Sciences’ antibody-drug conjugate Trodelvy demonstrated significant efficacy by outperforming standard chemotherapy in prolonging progression-free survival in patients with previously untreated metastatic triple-negative breast cancer (TNBC). This trial focused on patients not eligible for PD-1 or PD-L1 inhibitors due to lack of PD-L1 protein expression or ineligibility for immunotherapy. The study met its p…

Gilead notches another Phase 3 win for Trodelvy in triple-negative breast cancer

Gilead’s Trodelvy has passed another late-stage test in certain patients with metastatic triple-negative breast cancer (TNBC) — a win the company says could pave the way for the drug to become a foundational treatment in the ...

Breakthrough Clinical Trial: Trodelvy Achieves First Major Advance in 20 Years for Early-Stage Breast Cancer Treatment

New Phase 3 data reveals significant progression-free survival benefit in first-line metastatic TNBC treatment. First major advance in two decades. See full results.